News & Updates
Filter by Specialty:

Long-term semaglutide reduces diabetes risk
In a prespecified secondary analysis of the SELECT trial, long-term treatment with semaglutide allows more patients with prediabetes to regress to normoglycaemia while reducing progression to diabetes in some patients. However, semaglutide does not slow glycaemic progression over time.
Long-term semaglutide reduces diabetes risk
02 Aug 2024
Medication adherence prevents hospitalization among hypertensive, diabetic older adults
Older adults with diabetes and hypertension who regularly take their medications tend to have fewer hospitalizations or visits to the emergency room (ER), reports a study.
Medication adherence prevents hospitalization among hypertensive, diabetic older adults
01 Aug 2024
Nearly half of dementia cases preventable by tackling 14 risk factors
Nearly half of dementia cases could be prevented or delayed by addressing 14 modifiable risk factors starting from childhood, including two new risk factors – high LDL-cholesterol (LDL-C) level and untreated vision loss – according to a report of the 2024 Lancet Commission on dementia.
Nearly half of dementia cases preventable by tackling 14 risk factors
01 Aug 2024
Diet-induced weight loss tied to altered brain connectivity
Individuals with obesity who underwent a short-term, low-calorie diet demonstrate a multifaceted body response, including an increased brain connectivity in the limbic‒temporal network (emotion and memory) as well as hormone and eating behaviour changes that seem relevant for recovering the weight lost, a recent study has shown.
Diet-induced weight loss tied to altered brain connectivity
30 Jul 2024
Does race/ethnicity affect the safety, efficacy of semaglutide?
A post hoc analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trials has shown that the treatment effect and safety profile of semaglutide 2.4 mg, compared with placebo, are consistent across racial and ethnic subgroups.
Does race/ethnicity affect the safety, efficacy of semaglutide?
29 Jul 2024
Study presents alternate treatment approach for EARLY T2D
In the EARLY* trial, a 16-week intervention consisting of a 5:2 intermittent fasting meal replacement (5:2 MR) diet trumps two antidiabetic agents in improving glycaemic control and weight loss, as well as BP, TG, and HDL-C** levels in overweight or obese Chinese individuals with newly diagnosed type 2 diabetes (T2D).